ISCD Learning: ISCD Annual Meeting 2022

Intended Outcomes

The ISCD Annual Meeting provides a forum for the exchange of the most current and new clinically relevant and evidence-based information and research regarding skeletal health assessment. Additionally, prevention, diagnosis, and treatment (pharmacological and non-pharmacological) of osteoporosis and fracture risk is a major focus. Each of these categories will be explored through an international lens, as attendees experience presentations from areas around the world as technology continues to evolve and advance, this educational program will delve into the use of artificial intelligence tools that have the potential to capture underlying trends and patterns, while also covering machine and deep learning used to model the risk of fracture. This educational program is designed to enhance learner competence by providing targeted learning opportunities to enhance knowledge that learners may begin to use in their professional practice.

Learning Objectives

Determine which patients should be screened with a DXA exam and how the results should be properly interpreted.
Recognize the other tools available along with DXA (TBS, VFA) that can help determine a person’s fracture risk.
Describe how to best assess pediatric patients for disorders of bone health.
Identify appropriate therapeutic agents utilized to treat and manage patients with osteoporosis or other skeletal health disorders.
Describe the application of artificial intelligence tools for the prediction of osteoporosis and fracture prevention.
Explain how to best assess people with disabilities, spinal cord injury or other specific populations such as veterans (transgender) for fracture risk.
Select appropriate drug therapy for prevention and treatment of osteoporosis considering therapy efficacy, duration, and fracture history

Audience

The ISCD 2022 Annual Meeting content is designed for healthcare providers with an interest in skeletal health assessment, including specialists, generalists and technologists working in family medicine, general and internal medicine, endocrinology, rheumatology, obstetrics/gynecology, radiology, pediatrics, physical and occupational therapy, orthopedic surgery, nuclear medicine and research.

Statement of Need

Once seen as inevitable part of aging, osteoporosis has become a chronic condition, largely preventable and effectively treatable. New tools enable clinicians to assess skeletal health, determine the risk of fractures, screen patients for disease quickly, and refer them for treatment or targeted prevention measures, but only if the assessments are done in a quality manner. In order to improve the quality of patient care, this knowledge and information must be disseminated to healthcare professionals.

This activity is provided by the International Society for Clinical Densitometry.

ACCME Accreditation Statement

The International Society for Clinical Densitometry is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Contact Information: For information about the accreditation of this program, please contact ISCD at +1.860.259.1000 or inquire at education@iscd.org.

Physician Credit Designation Statement: The International Society for Clinical Densitometry designates this live educational activity for a maximum of 15.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit: Physicians will be required to complete an evaluation of each activity online after its conclusion. As part of that evaluation, they will claim the amount of credit commensurate with the extent of their participation in the activity. After completing the evaluation, a certificate will be generated that the physician may print to indicate credits earned.

ASRT Credit Statement

ASRT Category A Credit: ASRT has approved for a maximum of 18 Category A credits for this meeting. Individuals seeking ASRT Category A credit will need to remain in each live activity for the duration of the activity to be eligible to earn credit for that session, and attendance will be recorded automatically by the ISCD 2022 Annual Meeting Virtual platform. Individuals who remain during the entire session will be presented with the opportunity to complete an online evaluation of the session and claim the credit. Individuals will then be able to print out a certificate online.

Commercial Support and Disclosure

Policy on Commercial Support and Conflict of Interest: The ISCD maintains a policy on the use of commercial support, which ensures that all educational activities sponsored by the ISCD provide in-depth presentations that are fair, balanced, independent, and scientifically rigorous.

Disclosure of Commercial Support: This activity is supported by educational grants from Radius Health, Inc. and UCB.

Disclosure of Conflicts of Interest

ISCD requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Accredited Provider for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The speakers and moderators reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Lucas Andersen, BS Nothing to Disclose
Paul Anderson, MD Amgen (Self) : Consultant (Status: Ongoing); Medtronic (Self) : Consultant (Status: Ongoing); Radius Medical (Self) : Consultant (Status: Ongoing); Regeneration technology (Self) : Other Financial or Material Support (Status: Ongoing), Royalties (Status: Ongoing)
Henrique Arantes, CCD Nothing to Disclose
Carmen Gabriela Barbu, MD,PhD,CCD Amgen (Self) : Advisory Board (Status: Terminated --- 2021); Eli Lilly (Self) : Advisory Board (Status: Terminated --- 2020); Stada (Self) : speaker fee (Status: Terminated --- 2022); Theramex (Self) : Independent Contractor (Status: Terminated --- 2022)
Kaitlyn Barrett, DO Nothing to Disclose
Jyoti Bhattarai, MD Nothing to Disclose
Neil Binkley, MD Amgen (Self) : Consultant (Status: Ongoing); Radius (Self) : Research Support (Status: Ongoing)
Mary Bouxsein, PhD AgNovos Healthcare (Self) : Consultant (Status: Ongoing); Keros Therapeutics (Self) : Advisory Board (Status: Ongoing)
Bjoern Buehring, MD, CCD medimaps group (Self) : Research Support (Status: Ongoing)
Anthony Burns, MD MSc Nothing to Disclose
Pauline Camacho, MD Amgen (Self) : Speaker's Bureau / Teaching Engagements (Status: Terminated --- 2021); NPS Pharmaceuticals (Self) : Research Support (Status: Ongoing)
Bruno Camargos, PhD BM Camargos (Self) : Other Financial or Material Support (Status: Ongoing), Owner (Status: Ongoing)
Professor John Carey, MS GEHealthcare (Self) : Dinner x 2 in Paris at World Congress of Osteoporosis (Status: Terminated --- ), Other Financial or Material Support (Status: Terminated --- ); Health Research Board of Ireland (Self) : Research Support (Status: Ongoing); Hologic, Inc (Self) : Other Financial or Material Support (Status: Terminated --- 01/03/2022), Received 3 Slides modified and included in my presentation from Tom Kelly Hologic when I asked for a DB Update (Status: Terminated --- 01/03/2022)
Wing Chan, MD Nothing to Disclose
Angela Cheung, MD, PhD, FRCPC Amgen (Self) : Advisory Board (Status: Ongoing); Paladin Labs Inc. (Self) : Advisory Board (Status: Ongoing)
Christopher Cirnigliaro, PhD Nothing to Disclose
Anita Colquhoun, RTNM, MRT(N), CDT Nothing to Disclose
Felicia Cosman, MD Amgen (Self) : Advisory Board (Status: Ongoing), Speaker's Bureau / Teaching Engagements (Status: Ongoing); Enterabio (Self) : Consultant (Status: Ongoing); Obseva (Self) : Consultant (Status: Ongoing); Pfizer (Self) : Consultant (Status: Ongoing); Radius Health (Self) : Consultant (Status: Ongoing), Research Support (Status: Ongoing), Speaker's Bureau / Teaching Engagements (Status: Ongoing)
Carolyn Crandall, MD, CCD Nothing to Disclose
Beverley Catharine Craven, MD, MSc, FRCPC, FASIA, FCAHS Canadian Spinal Cord Injury Rehabilitation Association (Self) : Board Member/Advisory Panel (Status: Ongoing); CIHR (Self) : Operating Grant (Status: Ongoing), Other Financial or Material Support (Status: Ongoing), Research Support (Status: Ongoing); Coloplast (Self) : Other Financial or Material Support (Status: Ongoing), Unrestricted education funds (Status: Ongoing); Craig H Nielsen Foundation (Self) : Other Financial or Material Support (Status: Ongoing), Research Support (Status: Ongoing), Reviewer Stipend (Status: Ongoing); KITE Research Institute/University of Toronto (Self) : Other Financial or Material Support (Status: Ongoing), Research Support (Status: Ongoing), Sale and Distrbution of Knee positioners (Status: Ongoing); Ministry of Health Ontario (Self) : Research Support (Status: Ongoing); Praxis Spinal Research Institute (Self) : Board Member/Advisory Panel (Status: Ongoing), Consultant (Status: Ongoing), Research Support (Status: Ongoing); PVA (Self) : Other Financial or Material Support (Status: Terminated --- ), Travel Expenses (Status: Terminated --- )
Natalie Cusano, MD, MS, CCD Alexion (Self) : Speaker's Bureau / Teaching Engagements (Status: Ongoing); Ascendis (Self) : Data Safety Monitoring Board (Status: Ongoing), Other Financial or Material Support (Status: Ongoing); Shire/Takeda (Self) : Research Support (Status: Ongoing)
Johnathan Dallman, BS Nothing to Disclose
Lauren Farrier, MA Test Company (Self) : Employment (Status: Ongoing)
Carey Field, MD Nothing to Disclose
Lora Giangregorio, PhD Amgen (Self) : Other Financial or Material Support (Status: Ongoing), Received honorarium for lecture in February 2022 on exercise rehabilitation for osteoporosis (Status: Ongoing)
Ashraf Gorgey, PhD Nothing to Disclose
Didier Hans, PhD medimaps group (Self) : Board Member/Advisory Panel (Status: Ongoing), part time employee (Status: Ongoing), Shareholder (Status: Ongoing)
Karen Hind, PhD Nothing to Disclose
Rachel Hopkins, MD Nothing to Disclose
Lawrence Jankowski, CBDT Nothing to Disclose
Heidi Kecskemethy, MS Ed, RDN, CSP, CBDT Nothing to Disclose
Jennifer Kelly, DO, FACE, CCD Nothing to Disclose
Kyla Kent, BS Nothing to Disclose
Jenny Kiratli, PhD Nothing to Disclose
Lynn Kohlmeier, MD Alexion, Radius, Ascendis, Amgen (Self) : Advisory Board (Status: Ongoing), Research Support (Status: Ongoing), Speaker's Bureau / Teaching Engagements (Status: Ongoing)
Diane Krueger, CBDT, BS Amgen (Spouse/Partner) : Advisory Board (Status: Ongoing), Research Support (Status: Ongoing); Radius (Spouse/Partner) : Research Support (Status: Ongoing)
Joon Kiong Lee, FRCS, MS ORTHO Nothing to Disclose
Leon Lenchik, MD Nothing to Disclose
William Leslie, MD, MSc, CCD Nothing to Disclose
Mike Lewiecki, MD, FACP, FACE, CCD Amgen (Self) : Consultant (Status: Ongoing), Research Support (Status: Ongoing), Speaker's Bureau / Teaching Engagements (Status: Ongoing); Radius (Self) : Research Support (Status: Ongoing)
Eugene McCloskey, MD Amgen (Self) : Advisory Board (Status: Ongoing), Consultant (Status: Ongoing), Research Support (Status: Ongoing); Fresenius Kabi (Self) : Advisory Board (Status: Terminated --- ), Consultant (Status: Terminated --- ); Obseva (Self) : Advisory Board (Status: Terminated --- ), Independent Contractor (Status: Terminated --- ); UCB (Self) : Advisory Board (Status: Ongoing), Independent Contractor (Status: Ongoing)
Débora Meira Ramos Amorim, Nothing to Disclose
Jennifer Miller, MD, CCD Element Bars, Inc (Spouse/Partner) : Employment (Status: Ongoing), Shareholder (Status: Ongoing)
Paul Miller, MD, HDSc (honorary) Nothing to Disclose
Rachel Pessah-Pollack, FACE Boehringer Ingelheim/Eli Lilly (Self) : Advisory Board (Status: Ongoing); Health Monitor (Self) : Advisory Board (Status: Ongoing); Radius (Self) : Advisory Board (Status: Terminated --- 6/2020); Sanofi (Self) : Advisory Board (Status: Terminated --- 6/2020)
Catalina Poiana, MD, PhD, FACE, CCD Nothing to Disclose
Eric Rush, MD, FAAP Alexion (Self) : Consultant (Status: Ongoing), Research Support (Status: Ongoing), Speaker's Bureau / Teaching Engagements (Status: Ongoing); Ascendis (Self) : Advisory Committee/Board Member (Status: Ongoing); Biomarin (Self) : Consultant (Status: Ongoing), Speaker's Bureau / Teaching Engagements (Status: Ongoing); Inozyme (Self) : Consultant (Status: Ongoing); Ipsen (Self) : Advisory Board (Status: Ongoing); Ultragenyx (Self) : Consultant (Status: Ongoing), Research Support (Status: Ongoing), Speaker's Bureau / Teaching Engagements (Status: Ongoing)
John Schousboe, MD, PhD, CCD Nothing to Disclose
Jad Sfeir, MD, MS Nothing to Disclose
Vin Tangpricha, MD, PhD Nothing to Disclose
Karen Troy, PhD, CBDT Ossanex (Self) : Shareholder (Status: Ongoing); Scipher Medicine (Spouse/Partner) : Employment (Status: Ongoing)
Susan van der Kamp, RGN CDT Nothing to Disclose
Quinnlyn Walcott, BS Nothing to Disclose
Halley Wasserman, MD MS CCD Endocrine Society (Self) : Independent Contractor (Status: Ongoing), Other Financial or Material Support (Status: Ongoing), Question Writer for the Pediatric Endocrine Self-Assessment Program (Status: Ongoing); NIH (Self) : Research Support (Status: Ongoing); Ultragenyx (Self) : Research Support (Status: Ongoing)
Nelson Watts, MD, FACP, MACE, CCD Amgen and Radius (Self) : Speaker's Bureau / Teaching Engagements (Status: Ongoing)
Robert Wermers, Doctor Nothing to Disclose
CHRISTINE Williams, Nothing to Disclose
Chih-Hsing Wu, MD Nothing to Disclose
Hao Xu, MD Nothing to Disclose

The planners, managers, and reviewers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Reviewers:

Lawrence Jankowski, Nothing to Disclose
Suresh Kumar, Nothing to Disclose
William Leslie, Nothing to Disclose
Kelly Molinar-Kagain, Nothing to Disclose
Harold Rosen, Nothing to Disclose
Vani Selvan, MD, MSc, CCD Nothing to Disclose
Rebecca Shepherd, CBDT Nothing to Disclose

Planners and Managers:

Jennifer Bethke, Nothing to Disclose
Professor John Carey, MS GEHealthcare (Self) : Dinner x 2 in Paris at World Congress of Osteoporosis (Status: Terminated --- ), Other Financial or Material Support (Status: Terminated --- ); Health Research Board of Ireland (Self) : Research Support (Status: Ongoing); Hologic, Inc (Self) : Other Financial or Material Support (Status: Terminated --- 01/03/2022), Received 3 Slides modified and included in my presentation from Tom Kelly Hologic when I asked for a DB Update (Status: Terminated --- 01/03/2022)
Christopher Cirnigliaro, PhD Nothing to Disclose
Jennifer Kelly, DO, FACE, CCD Nothing to Disclose
Rachel Pessah-Pollack, FACE Boehringer Ingelheim/Eli Lilly (Self) : Advisory Board (Status: Ongoing); Health Monitor (Self) : Advisory Board (Status: Ongoing); Radius (Self) : Advisory Board (Status: Terminated --- 6/2020); Sanofi (Self) : Advisory Board (Status: Terminated --- 6/2020)
John Schousboe, MD, PhD, CCD Nothing to Disclose

Important ISCD Policy

Release of Liability: The lecturers and authors shall not be held liable or responsible to any person or entity with respect to any loss or damage alleged to be caused directly or indirectly by the information presented at this program.

Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The ISCD does not recommend the use of any agent outside of labeled indications.

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contra indications, and warnings.

Acknowledgment of Support: Commercial organizations that provide financial support for the ISCD Annual Meeting are key partners who play a vital role in the success of this event. It is the policy of ISCD to maintain independence from commercial support in the planning and implementation of continuing education activities. All decisions regarding the educational content or speaker selection for this activity have been made solely by the 2022 ISCD Annual Meeting Program Committee.

Equal Opportunity Statement: ISCD is committed to equal opportunity and nondiscrimination in all programs and services and does not discriminate on the basis of race, ethnicity, color, religion, sex, including marital status, national origin, ancestry, age sexual orientation, disability, or veteran status.

Liability Disclaimer Statement: ISCD shall not be held liable for personal injury, death, property damage, or loss suffered by a participant in connection with any program or service, whether due to the negligence of staff or others.

Americans with Disabilities Statement: ISCD, in support of the spirit of the Americans with Disabilities Act (ADA), endeavors to honor all requests for reasonable accommodations in order for participants and/or members to achieve equal access to all programs and services.

Disclaimer: The information and suggestions presented at the courses, seminars, and other programs sponsored by ISCD and other collaborating societies are subject to change and therefore should serve only as a foundation for further investigation and study. Any forms presented at our seminars or programs are samples only and are not necessarily authoritative. All information, procedures, and forms contained or used in such seminars or programs should serve only as a guide for use in specific situations.

Disability Compliance: The ISCD fully complies with the legal requirements of the Americans with Disabilities Act. If you require special accommodations to participate fully in the ISCD program, please contact us as soon as possible so we can make appropriate accommodations. You can make accommodation requests by calling 860.259.1000 or sending via email to education@iscd.org.